Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bioasis Technologies Inc. V.BTI

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.


TSXV:BTI - Post by User

Comment by KayakerBCon Dec 31, 2022 3:00pm
69 Views
Post# 35198590

RE:RE:RE:RE:RE:RE:RE:Midatech at $1.0475

RE:RE:RE:RE:RE:RE:RE:Midatech at $1.0475So what dictates the price of 1 ADS in Biodexa Therapeutics?

I think the current MTP price on the NASDAQ reflects the dilution, acquisition, and market opinion of the deal.  Those are ADS.  My expectation is the Biodexa (just Midatech renamed) will begin trading somewhere around the last MTP price and the market will take it from there.


<< Previous
Bullboard Posts
Next >>